will allow it to chart a path forward for its neurology genomic medicine pipeline as it prepares to initiate expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small ...
The company prepares to initiate the expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and file an anticipated Clinical Trial ...
The company prepares to initiate the expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and file an anticipated Clinical Trial ...
It expects to begin clinical studies (phase I/II) on ST-503 for the treatment of intractable pain due to idiopathic small fiber neuropathy in mid-2025. Several years ago, we shocked our members by ...
Sangamo added that it expects the enrollment of patients in a Phase 1/2 study of a therapy for idiopathic small fiber neuropathy this year. “We remain focused on advancing our wholly owned neurology ...
Sangamo’s plans to initiate enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy and the anticipated timing thereof; Sangamo’s plans to submit a CTA ...
Enrollment for a Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy is expected to begin in mid-2025, and a Clinical Trial Authorisation submission for a prion disease program is ...
Enrollment for a Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy is expected to begin in mid-2025, and a Clinical Trial Authorisation submission for a prion disease program is planned ...
The company’s pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs ... Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025, and file ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback